Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Theakine Prost is a nutraceutical dietary supplement developed by Adamas Biotech, a subsidiary of Cube Labs. It is formulated with a standardized green tea extract, specifically Theaphenon E®, which contains a high concentration (90%) of catechins. Administered orally, the product is intended to support prostate health and alleviate Lower Urinary Tract Symptoms (LUTS) associated with conditions such as benign prostatic hyperplasia (BPH), infections, and overactive bladder. The mechanism of action involves the antioxidant, anti-inflammatory, and antimicrobial properties of green tea catechins, which provide protective effects on the prostate and lower urinary tract. The product was officially registered with the Italian Ministry of Health in November 2024 and is positioned for strategic distribution partnerships within the urology sector.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Theakine Prost.